Please login to the form below
Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more
Highlights from the world of pharma, biotech and healthcare
NICE set to reject Kyowa Kirin’s Crysvita for XLH
Committee says the rare disease therapy isn’t value for money
Sage surges after depression drug gets rapid path to approval
Will be able to file a marketing application based on its phase II trial
UK, Germany back routine use of J&J’s Tremfya
The IL-23 inhibitor is currently being assessed in other EU countries
AbbVie, Roche get FDA OK for broader use of Venclexta
The drug is tipped to become a $2.5bn product by 2024
Roche’s MabThera ends drug drought for serious skin disease
As biosimilars seize market share, Roche finds ways to extend blockbuster's revenues
Merck’s Brexit contingency plan? Stockpile medicines
As UK's Brexit plans remain in disarray, big pharma is making contingency plans
Novartis bribery probe in Greece ‘could affect general election’
The pharma giant allegedly gave “bundles of cash” to civil servants, doctors and politicians
NICE backs Tesaro’s Zejula via the CDF
Recommends the drug for second-line use in ovarian cancer patients
Moving times
Continuity and stability are vital when it comes to the EMA's relocation when it leaves London
-
SMC gives green light for Amgen’s KyprolisThe committee also gives verdict on three other products
-
Facing the new wave of biosimilarsDon’t drown out the patient voice, says advocacy group
-
PMCPA takes AZ to task over asthma drug press release Concluded that the data in the release had not been “placed in context”
-
Pfizer’s Xeljanz picks up a third indication in the USThe JAK inhibitor can now treat patients with ulcerative colitis
-
ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-lineRecommends the drug should only be used in patients who have exhausted other prevention options
-
Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and moreIt's not just the GDPR's big day, plus news from Medigene and Pfizer
-
Digital skills gap hinders UK healthcare innovationReport calls for greater emphasis on HCPs’ digital and data literacy education
-
FDA starts review of Sanofi’s oral type 1 diabetes drug -
FDA clears Dova drug for liver-related low blood plateletsDrug is in the same class as Novartis’ Promacta/Revolade
Latest regulatory appointments
-
Professor Carole Longson moves from NICE to the ABPIShe joins the UK pharma body as its chief scientific officer
-
MedTech Europe appoints new board of directors
Chair of the board Michelle Brennan is among those newly elected
-
Greg Perry joins IFPMA as assistant director generalWill move to the global industry body from the Medicines Patent Pool
-
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance
He joins the biopharma from Tang Capital Management
-
IFPMA names new communications director
Helen Gallagher joins the association from Ferring Pharmaceuticals
Featured jobs
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Medical Writer, Healthcare Advertising
-
£35 - £45, 000 benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Senior Strategic Planner, Healthcare Brand Communications, Londo...
-
Competitive Salary
- Senior Account Director or Business Unit Director, Healthcare Ad...
-
C£60, 000 – £70, 000 benefits
- Science Writer – Healthcare Advertising
-
Salary TBC
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Account Director, Training & Medical Communications, London
-
Competitive Salary
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
Competitive salary
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Scientific Engagement Director
-
Salary will be dependant on experience
- Medical Writer - Medical Communications
-
£30, 000 - £40, 000 according to skills and experience plus benefits
Subscribe to our email news alerts
- Roche starts new late-stage trials of Alzheimer’s candidate
- AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib
- Moving annual total (MAT)
- More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease
- Key success factor (KSF)
- Commentary: Roseanne’s racist tweet and Sanofi’s swift and surprising riposte
PMHub
Star
Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...
Latest intelligence
- The truth is out there: Patients first
- Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
- mHealth: The revolution will not be digital
- Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
- Medical information in precision medicine
- Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....
Quick links
Infographics
